[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Aplastic Anemia pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 84 pages | ID: A4C50E2E1B64EN

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Aplastic Anemia PIPELINE HIGHLIGHTS
Aplastic Anemia is one of the widely researched conditions during 2020 with 15 companies actively focusing on realizing pipeline’s potential. Development of Aplastic Anemia medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Aplastic Anemia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Aplastic Anemia.

Good progress is anticipated during 2020 and 2021 with Aplastic Anemia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Aplastic Anemia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
The “Aplastic Anemia pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Aplastic Anemia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Aplastic Anemia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Aplastic Anemia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Aplastic Anemia DRUG PROFILES
Aplastic Anemia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators

Both small size and large size pharmaceutical companies are investing their resources in Aplastic Anemia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Aplastic Anemia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 15 Aplastic Anemia companies including company overview, key snapshot, contact information, and their strategies on accelerating Aplastic Anemia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Acceleron Pharma Inc, Amgen Inc, Angiocrine Bioscience, ASC Therapeutics Inc, BioLineRx Ltd, Cell Source Inc, Cellenkos Inc, Elixirgen Therapeutics LLC, F. Hoffmann-La Roche Ltd, Gamida Cell Ltd, HemoGenyx LLC, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, Regen BioPharma Inc, Regeneron Pharmaceuticals

  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Aplastic Anemia
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners

1.1 Aplastic Anemia- Disease overview
1.2 Aplastic Anemia- Market Size
1.3 Aplastic Anemia- Companies Involved


2.1 Aplastic Anemia Pipeline by Phase
2.2 Aplastic Anemia Pipeline by Mechanism of Action
2.3 Aplastic Anemia Pipeline by Route of Administration
2.4 Aplastic Anemia Pipeline- New Molecular Entities
2.5 Aplastic Anemia Pipeline- Orphan Drug Designation/ Special Designation


3.1 Current Status
3.2 Aplastic Anemia Drug Snapshot
3.3 Aplastic Anemia Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Acceleron Pharma Inc Aplastic Anemia Pipeline Insights and Clinical Trials
4.2 Amgen Inc Aplastic Anemia Pipeline Insights and Clinical Trials
4.3 Angiocrine Bioscience Aplastic Anemia Pipeline Insights and Clinical Trials
4.4 ASC Therapeutics Inc Aplastic Anemia Pipeline Insights and Clinical Trials
4.5 BioLineRx Ltd Aplastic Anemia Pipeline Insights and Clinical Trials
4.6 Cell Source Inc Aplastic Anemia Pipeline Insights and Clinical Trials
4.7 Cellenkos Inc Aplastic Anemia Pipeline Insights and Clinical Trials
4.8 Elixirgen Therapeutics LLC Aplastic Anemia Pipeline Insights and Clinical Trials
4.9 F. Hoffmann-La Roche Ltd Aplastic Anemia Pipeline Insights and Clinical Trials
4.10 Gamida Cell Ltd Aplastic Anemia Pipeline Insights and Clinical Trials
4.11 HemoGenyx LLC Aplastic Anemia Pipeline Insights and Clinical Trials
4.12 Jiangsu Hengrui Medicine Co Ltd Aplastic Anemia Pipeline Insights and Clinical Trials
4.13 Novartis AG Aplastic Anemia Pipeline Insights and Clinical Trials
4.14 Regen BioPharma Inc Aplastic Anemia Pipeline Insights and Clinical Trials
4.15 Regeneron Pharmaceuticals Aplastic Anemia Pipeline Insights and Clinical Trials



6.1 Sources and Methodology
6.2 Contact Information

More Publications